Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.
Compounded GLP-1s occupy a strange place in medicine right now. Millions of patients used compounded semaglutide or tirzepatide during the 2022–2024 shortage era, often paying $150–$350 a month instead of $1,000–$1,600 for a brand pen. Then the FDA declared the shortages resolved, the mass-production window closed, and the market fractured into legitimate patient-specific compounding on one side and a grey zone of “research peptide” websites and salt-form products on the other.
That leaves patients with a genuinely hard question: how do you tell a well-run 503A pharmacy from a bad one? Having spent 27 years inside sterile compounding operations, I can tell you the difference is visible if you know what to ask for. This guide walks through how compounding actually works, what changed after the shortage list era ended, the red flags that should end a conversation immediately, and the exact documents a quality pharmacy will hand you without hesitation.
See our complete semaglutide guide for STEP trial data, titration schedules, and side-effect management.
Key Takeaways
- › Compounded semaglutide contains the same active molecule studied in STEP 1, where patients lost a mean 14.9% of body weight over 68 weeks (Wilding et al., NEJM, 2021). The molecule doesn’t know which pharmacy made it; quality control is what differs.
- › The FDA shortage-list era is over. In 2026, compounded GLP-1s are legal only as patient-specific 503A prescriptions with a documented clinical reason, not as mass-produced copies of Ozempic or Zepbound.
- › Semaglutide “sodium” or “acetate” salt forms are not the FDA-approved active ingredient. A pharmacy or website selling salt forms is the single clearest red flag in this market.
- › A legitimate sterile 503A runs potency, sterility, and endotoxin testing and can produce a certificate of analysis for your specific batch. If they can’t or won’t, walk away.
- › Cost typically runs $150–$400/month compounded versus $1,000–$1,600 list price for brand pens, but the savings only make sense with provider oversight and verified pharmacy quality.
What Is Compounding, and What Does 503A Actually Mean?
Compounding is the preparation of a customized medication for an individual patient under a prescription. It’s been part of pharmacy practice for as long as pharmacy has existed. Federal law recognizes two pathways: 503A pharmacies, which prepare patient-specific prescriptions, and 503B outsourcing facilities, which produce larger batches under FDA-registered, cGMP conditions for office use.
A 503A pharmacy is licensed and inspected by its state board of pharmacy. It compounds from pharmaceutical-grade active ingredients sourced from FDA-registered suppliers, and each preparation is tied to a named patient and a prescriber. Sterile injectables, which is what a compounded GLP-1 is, must be prepared under USP <797> sterile compounding standards: cleanroom environments, environmental monitoring, media-fill validation of technique, and beyond-use dating supported by testing.
This matters because “compounded” is not a euphemism for “unregulated.” A properly operating sterile 503A is one of the more heavily inspected corners of pharmacy. The problem is that the GLP-1 boom pulled in operators who never built that infrastructure, and from the outside their websites look identical to the good ones.
Why Do Compounded GLP-1s Exist in the First Place?
Four reasons, and cost is only the first. Brand semaglutide and tirzepatide list between $1,000 and $1,600 per month, and insurance coverage for the obesity indication remains inconsistent. Compounded versions typically run $150–$400 per month. For a medication the STEP 4 trial showed must be continued long-term to hold results (Aronne et al., JAMA, 2021, PMID 33755728), that price gap decides who gets treated at all.
The second reason is dose flexibility. Brand pens come in fixed steps. A vial-and-syringe compounded prescription lets a provider hold a patient at 0.4 mg, or bridge between steps, or titrate more slowly than the label schedule. In clinical practice that flexibility is often what keeps a nausea-prone patient on therapy.
Third is access. During the 2022–2024 shortages, brand pens were simply unavailable for months at a time. Compounding pharmacies were the legal relief valve, which is exactly what the compounding statutes were designed to allow.
Fourth, compounding permits clinically justified added ingredients. Common examples are cyanocobalamin (vitamin B12), pyridoxine (B6), or glycine in the same vial, usually intended to support energy or blunt nausea during titration. These combinations are reasonable when a prescriber documents why the individual patient needs them. When they exist mainly to make a prescription look “different enough” from the brand product, that’s a legal fig leaf, not personalization, and regulators know the difference.
Our tirzepatide deep dive covers the dual GIP/GLP-1 mechanism and the full SURMOUNT results.
What Changed When the FDA Shortage List Era Ended?
During an FDA-declared shortage, compounders may legally prepare what are otherwise “essentially copies” of the branded drug. Tirzepatide came off the FDA shortage list in late 2024, and semaglutide followed in early 2025, with enforcement grace periods for 503A pharmacies and 503B facilities expiring in spring 2025 (FDA Drug Shortages database; FDA compounding guidance).
Here’s what that means in 2026. Mass-marketed “compounded semaglutide, same as Ozempic, subscribe now” is no longer a lawful model. What remains lawful is traditional 503A compounding: a licensed prescriber writes a patient-specific prescription that differs from the commercial product for a documented clinical reason, such as a dose the pens don’t offer, a slower titration in a patient who failed the standard schedule, or a medically necessary added ingredient.
Practically, the market sorted into three tiers. Legitimate 503A pharmacies working through telehealth or local providers with real clinical documentation. Offshore and “research use only” websites selling vials with no prescription, no pharmacy license, and no accountability. And salt-form sellers, which deserve their own section because they’re the most deceptive of the three.
We compare every access path side by side in Ozempic vs Wegovy vs compounded semaglutide.
Salt Forms vs Base Peptide: The Red Flag That Ends the Conversation
The semaglutide in Ozempic, Wegovy, and every clinical trial you’ve read about is semaglutide base. Some sellers instead offer “semaglutide sodium” or “semaglutide acetate,” which are different chemical salt forms. The FDA has stated publicly that these salts are not the same active ingredient as the approved drug, and that it’s not aware of any legal basis for compounding them (FDA compounding guidance on semaglutide).
Why do salt forms exist in this market at all? Because they’re cheaper to source through chemical supply channels that sidestep pharmaceutical-grade API requirements. No STEP or SURMOUNT trial ever tested them. Their absorption, potency, and stability in a subcutaneous injection are unestablished.
The screening question is simple: ask the pharmacy, in writing, whether the product is semaglutide base or a salt form. A legitimate pharmacy answers “base” instantly and can show the API source on the certificate of analysis. Any hedging, or any listing that says “sodium” or “acetate,” ends the conversation. The same logic applies to tirzepatide.
How Do You Vet a Compounding Pharmacy? A Pharmacist’s Checklist
Everything below is information a quality pharmacy already has on hand, because their own quality program requires it. You’re not asking for favors. You’re asking them to show you paperwork they generate for every batch anyway. In my experience, the speed and confidence of the response tells you nearly as much as the documents themselves.
Dr. Nguyen’s Clinical Perspective: When I review a COA, I look past the purity number everyone fixates on. First, does the lot number on the certificate match the lot number printed on the vial in your hand? A “representative” COA with no lot match is marketing, not quality control. Second, who performed the testing: an independent third-party lab with its own letterhead, or the pharmacy grading its own homework? Third, for an injectable, are sterility and endotoxin results actually on the panel? Potency tells you the drug is in the vial. Endotoxin tells you it’s safe to inject. I’ve seen beautiful 99% purity certs from operations I wouldn’t let touch a syringe, and I’ve seen modest-looking two-page COAs from pharmacies whose cleanrooms were immaculate. The paperwork pattern, not any single number, is what separates them.
Brand Pen vs Compounded: A Side-by-Side Comparison
Neither option is universally better. Brand pens carry the full FDA approval package and manufacturer quality assurance. Compounded prescriptions offer cost access and dose flexibility, and shift the quality-verification burden onto the prescriber and the patient. Here’s how they compare on the factors that actually drive the decision:
| Factor | Brand Pen (Wegovy / Zepbound) | Compounded (503A) |
|---|---|---|
| Monthly cost | $1,000–$1,600 list; less with coverage or manufacturer savings programs | $150–$400 self-pay, typically including provider visits at telehealth clinics |
| Dose flexibility | Fixed pen increments only | Any prescribed dose; slower titration and intermediate steps possible |
| Insurance | Sometimes covered; obesity indication frequently excluded | Almost never covered; priced for self-pay |
| Availability (2026) | Shortages resolved; supply generally reliable | Patient-specific prescriptions only, with documented clinical justification |
| What you must verify | Pharmacy is dispensing genuine product (counterfeit pens exist) | State license, PCAB status, batch COA, sterility/endotoxin testing, base peptide |
One point worth repeating: the active molecule is the same. Semaglutide base from a properly sourced API behaves like the semaglutide that produced 14.9% mean weight loss in STEP 1 (PMID 33567185) and sustained 15.2% loss at two years in STEP 5 (Garvey et al., Nature Medicine, 2022, PMID 36216945). Pharmacology doesn’t change with the label. Quality assurance does.
Want Physician-Supervised Compounded GLP-1 Therapy?
Metabolic Regen MD offers compounded semaglutide and tirzepatide under licensed provider oversight, with baseline labs, personalized titration, and vetted pharmacy sourcing.
What Do Titration and Realistic Expectations Look Like?
Compounded or branded, GLP-1 titration follows the same physiology. Semaglutide typically starts at 0.25 mg weekly and escalates every four weeks toward a 1.7–2.4 mg maintenance range. Tirzepatide starts at 2.5 mg weekly and steps toward 10–15 mg. The starting doses aren’t therapeutic; they exist so your GI tract can adapt to slowed gastric emptying (Drucker, Cell Metab, 2018, PMID 29617641).
This is where compounded prescriptions genuinely shine. A provider can hold a sensitive patient at an off-label intermediate dose for eight weeks instead of four, or step from 0.5 mg to 0.75 mg instead of jumping to 1.0 mg. We’ve found that patients who titrate slower quit less. Many patients also plateau well below the maximum dose and never need to reach it.
Set expectations against the trial data, not against social media. Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks in STEP 1. Tirzepatide 15 mg produced 20.9% at 72 weeks in SURMOUNT-1 (Jastreboff et al., NEJM, 2022, PMID 35658024), and beat semaglutide head-to-head in SURMOUNT-5 with 20.2% versus 13.7% (Aronne et al., NEJM, 2025, PMID 40353578). Expect slow movement in month one, meaningful loss between months two and nine, and a plateau afterward. The plateau is the drug working, not failing.
Maintenance dosing is covered in our semaglutide guide.
Side Effect Management Basics
GI effects dominate: nausea, constipation, reflux, and occasional vomiting, concentrated in the days after each dose increase. The playbook is consistent. Eat smaller meals and stop at “no longer hungry” rather than “full.” Keep fat intake modest for 48–72 hours after each injection. Hydrate aggressively, and use magnesium citrate or glycinate at night for constipation. Dose at bedtime so peak nausea overlaps sleep. If a dose step is miserable, drop back and hold; there’s no prize for reaching maintenance on schedule.
Dr. Nguyen’s Clinical Perspective: The patients who abandon GLP-1 therapy almost always quit between weeks four and twelve, during dose escalation, and SURMOUNT-4 shows why that’s costly: staying on therapy preserved a 25.3% total reduction while stopping led to substantial regain (Aronne et al., JAMA, 2024, PMID 38078870). In functional practice, one adjunct I find underexplored is BPC-157, a gastric pentadecapeptide with extensive preclinical evidence of GI cytoprotection (Sikiric et al., Curr Pharm Des, 2011, PMID 21548867). For researchers studying gut-protective peptide mechanisms alongside incretin signaling, Elite Biologix supplies research-grade BPC-157 at ≥98% verified purity with batch-specific certificates of analysis for qualified research environments.
Who Should NOT Use Compounded GLP-1s?
Some exclusions apply to all GLP-1 therapy, compounded or branded. Personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication. History of pancreatitis warrants a serious risk-benefit conversation. Severe gastroparesis will get worse on these drugs. Anyone pregnant, breastfeeding, or planning conception within two months should not start. Patients with active gallbladder disease need evaluation first.
Other exclusions are specific to the compounded route. If your insurance covers the brand pen affordably, take the brand pen; you gain the manufacturer’s quality system at no extra cost. If you can’t obtain provider oversight with baseline labs and follow-up, you shouldn’t be on any version of these drugs, and a vial without monitoring is the worst configuration. And if the only available source fails the vetting checklist above, sells salt forms, or ships without a prescription, no price justifies the risk of an unverified injectable.
A last category deserves honesty: people near a healthy weight seeking cosmetic loss. The trials enrolled patients with obesity or overweight plus comorbidity. Outside that population, the risk-benefit math hasn’t been studied and the muscle-loss downside grows proportionally larger.
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy?
When properly made, yes at the molecular level. A legitimate 503A compounds semaglutide base, the identical active ingredient in Ozempic and Wegovy, from an FDA-registered API supplier. What differs is the delivery format (vial versus pen), the excipients, and the quality system behind it. Salt forms like semaglutide sodium are not the same drug and were never tested in the STEP trials.
Are compounded GLP-1s still legal in 2026?
Yes, but narrowly. With the FDA shortages resolved, compounders can no longer produce “essentially copies” of the brand products at scale. A 503A pharmacy may still dispense a patient-specific prescription that differs clinically from the commercial drug, such as a custom dose or a documented medically necessary modification, written by a licensed prescriber for a named patient.
How much does compounded semaglutide or tirzepatide cost?
Typical self-pay pricing runs $150–$400 per month depending on the drug, dose, and whether provider visits are bundled. That compares with $1,000–$1,600 list price for brand pens. Prices dramatically below that range, especially under $100 with no prescription required, usually indicate a research-chemical seller or salt-form product rather than a licensed pharmacy.
What should a certificate of analysis actually show?
Four things: a lot number matching the vial you received, an independent third-party testing lab, a potency result confirming the labeled concentration, and for injectables, sterility (USP <71>) and bacterial endotoxin (USP <85>) results. A generic “sample” COA without your batch’s lot number doesn’t verify anything about the product in your hands.
What’s the difference between a 503A pharmacy and a 503B facility?
A 503A pharmacy compounds patient-specific prescriptions under state board of pharmacy oversight. A 503B outsourcing facility registers with the FDA, follows full cGMP manufacturing standards, and produces larger batches, typically for clinics and hospitals rather than individual prescriptions. Most patients accessing compounded GLP-1s through telehealth receive 503A preparations tied to their own prescription.
For a deeper cost and access breakdown, read Ozempic vs Wegovy vs compounded semaglutide.
Conclusion
Compounded GLP-1s are neither the scam their critics describe nor the frictionless bargain their marketers promise. They’re a legitimate, legally narrower-than-2023 pathway that works well under three conditions: a real prescriber relationship, a documented clinical reason for compounding, and a pharmacy that passes the vetting checklist without flinching. The molecule that delivered the STEP and SURMOUNT results doesn’t care where it was vialed. Everything else about safety does.
Do the verification work once, before the first injection, and the compounded route can deliver brand-trial pharmacology at a quarter of the price. Skip it, and you’re injecting an unverified product on faith.
Want physician-supervised compounded GLP-1 therapy? Metabolic Regen MD offers compounded semaglutide and tirzepatide under licensed provider oversight, with pharmacy sourcing already vetted against the standards in this guide.
Dr. Nguyen recommends baseline labs before starting any GLP-1 protocol: HbA1c, fasting insulin, comprehensive metabolic panel, lipids, and TSH at minimum. Order at-home through Private MD Labs (code MICHAEL166 for 15% off).
Full titration schedules and side-effect management live in our semaglutide weight loss guide.
References
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. PMID: 33567185
- Garvey WT, et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.” Nature Medicine, 2022. PMID: 36216945
- Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4).” JAMA, 2021. PMID: 33755728
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. PMID: 35658024
- Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).” New England Journal of Medicine, 2025;393(1):26-36. PMID: 40353578
- Aronne LJ, et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4).” JAMA, 2024. PMID: 38078870
- Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metabolism, 2018. PMID: 29617641
- Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design, 2011. PMID: 21548867
- U.S. Food & Drug Administration. “Outsourcing Facility Information — Human Drug Compounding.” https://www.fda.gov/drugs/human-drug-compounding/outsourcing-facility-information
- U.S. Food & Drug Administration. “FDA Drug Shortages — Semaglutide and Tirzepatide status.” https://www.accessdata.fda.gov/scripts/drugshortages/
This article is for educational and informational purposes only and does not constitute medical advice. Compounded semaglutide and tirzepatide are prescription medications dispensed by licensed pharmacies under prescriber oversight. Individual results vary.